Straten Per thor, Becker Jürgen C
Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark.
J Invest Dermatol. 2009 Dec;129(12):2743-5. doi: 10.1038/jid.2009.204.
Adoptive cell therapy (ACT) for metastatic cancer is the focus of considerable research effort. Rosenberg's laboratory demonstrated a 50% response rate in stage IV melanoma patients treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) and high-dose IL-2 administered after nonmyeloablative conditioning (Dudley et al., 2002a). Because early attempts to use expanded TILs in melanoma therapy failed to demonstrate better efficacy than high-dose IL-2 (Rosenberg et al., 1994), the efficacy of TILs and nonmyeloablative conditioning in combination implies that patient conditioning is crucial to clinical success. The 2002 data represent a milestone in cellular cancer therapy and a turning point for ACT in cancer treatment.
转移性癌症的过继性细胞疗法（ACT）是大量研究工作的重点。罗森伯格实验室证明，接受非清髓性预处理后给予体外扩增的肿瘤浸润淋巴细胞（TIL）和高剂量白细胞介素-2治疗的IV期黑色素瘤患者，缓解率达50%（达德利等人，2002年a）。由于早期在黑色素瘤治疗中使用扩增TIL的尝试未能证明其疗效优于高剂量白细胞介素-2（罗森伯格等人，1994年），TIL与非清髓性预处理联合使用的疗效表明，患者预处理对临床成功至关重要。2002年的数据代表了细胞癌症治疗的一个里程碑，也是ACT在癌症治疗中的一个转折点。
